Drug General Information
Drug ID	D0RZ0N
Former ID	DIB010341
Drug Name	FR-62765
Drug Type	Small molecular drug
Indication	Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1]		Terminated	[529820]
Company	Fujisawa Pharmaceutical Co Ltd
Structure		Download 2D MOL 3D MOL
Formula	C16H18O5
Canonical SMILES	C1(=C(C(=O)OC1CCC(=O)OCC)OC)c1ccccc1
CAS Number	CAS 105346-34-7
PubChem Compound ID	128354
Target and Pathway
Target(s)	Aldose reductase	Target Info	Modulator	[529820]
BioCyc Pathway	Methylglyoxal degradation III
	Acetone degradation I (to methylglyoxal)
KEGG Pathway	Pentose and glucuronate interconversions
	Fructose and mannose metabolism
	Galactose metabolism
	Glycerolipid metabolism
	Metabolic pathways
NetPath Pathway	IL1 Signaling Pathway
	TGF_beta_Receptor Signaling Pathway
PathWhiz Pathway	Fructose and Mannose Degradation
	Pyruvate Metabolism
	Pterine Biosynthesis
	Glycerolipid Metabolism
	Galactose Metabolism
WikiPathways	Metapathway biotransformation
	Polyol Pathway
	Metabolism of steroid hormones and vitamin D
References
Ref 529820	Studies on WF-3681, a novel aldose reductase inhibitor. IV. Effect of FR-62765, a derivative of WF-3681, on the diabetic neuropathy in rats. J Antibiot (Tokyo). 1991 Apr;44(4):441-4.
Ref 529820	Studies on WF-3681, a novel aldose reductase inhibitor. IV. Effect of FR-62765, a derivative of WF-3681, on the diabetic neuropathy in rats. J Antibiot (Tokyo). 1991 Apr;44(4):441-4.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.